Australia's most trusted
source of pharma news
Thursday, 12 March 2026
Posted 11 March 2026 PM
The vagaries of the Australian HTA processes have been thrown into stark relief with the short subsidised life of a first-in-class drug, which took more than twice as long to hit the PBS as it spent subsidised before it was removed.
When Onpattro made the PBS in August 2024 it became the first RNA interfering molecule to be listed, the first subsidised treatment for hereditary transthyretin-mediated amyloidosis, and the first of Alnylam's drugs to hit the Australian market.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.